The Future of Cell Therapy – Today
At Lyell, we are advancing next-generation CAR T-cell product candidates for patients with cancer.
Dedicated to Delivering Lasting Remissions
Our purpose is to give people with cancer and their loved ones the gift of time.
Next-Generation CAR T-Cell Therapies
We are building an industry-leading, clinical-stage pipeline of CAR T-cell product candidates designed to be one-time treatments that deliver lasting remissions.
Our goal is to fully realize the curative potential of cell therapy for patients with cancer. To achieve this, we are pioneering novel approaches designed to generate T cells with potent cancer cell killing capabilities that drive long-lasting clinical responses.
In hematologic malignances, our goal is to meaningfully improve outcomes over first-generation CAR T-cell therapies. For solid tumors, we are aggressively progressing the next wave of cell therapy innovation.
We believe next-generation cell therapy has the potential to offer patients with cancer what they’re looking for — a return to their normal lives without ongoing treatment.
To achieve this, we start by identifying promising cancer targets. We then arm our CAR T-cell product candidates with enhancements designed to boost the extraordinary cancer-fighting ability of T cells.
Our enhancements include innovative CAR constructs, technologies, and manufacturing protocols designed to endow
T cells with more potent and durable cancer cell killing capabilities.
With a commitment to quality and innovation, we own and operate our own manufacturing facility. This gives us control over our supply chain and each cell product we make.
Pipeline
Learn about our clinical-stage pipeline of next-generation CAR T-cell product candidates for cancers with significant unmet medical need.
Join Us
Interested in doing some of the best work of your life? Learn about our team and becoming a Lyellite.